A farmavita member is offering aa immune-supporting supplement product for Europe, USA, MIDDLE EAST, & AFRICA.

 Introduction and initial research
Research on this patented formulation (containing L-methionine, magnesium, vitamin B6, B12 and folic acid), started as early as 1992, at the University of Pretoria, South Africa. Pilot studies were conducted on 20 – 30 HIV positive patients, under supervision of one of South Africa’s top HIV/AIDS specialists, Dr Steven Miller. Due to the excellent results achieved, a follow-up study on approximately 100 patients was done with the permission of the South African Medicine Control Council, first for six months, and then for a follow-up period of up to two years. The results of this trial were presented at the International HIV conference in Yokohama, Japan in 1994.

With the help and financial support of the Industrial Development Corporation (IDC), an even larger, longer-term double-blind, placebo-controlled trial was started in 1997. Preliminary results of this trial were presented at the International HIV/AIDS Conference in Geneva, Switzerland in 1998, and the Amino Acid Conference in Vienna, Austria in 2001.

These clinical trials were done under the registered trademark of Equimmune, and were aimed specifically at the HIV/AIDS market.

Bio Boost formulation
A second product was formulated, with a slightly adjusted dosage, under the trademark Bio Boost. The formulation proved to be effective for any patient with a low or deficient immune system, whether due to chronic fatigue, extreme stress and tension or common cold and flu.

A farmavita member is offering aa immune-supporting supplement product for Europe, USA, MIDDLE EAST, & AFRICA.

 Introduction and initial research
Research on this patented formulation (containing L-methionine, magnesium, vitamin B6, B12 and folic acid), started as early as 1992, at the University of Pretoria, South Africa. Pilot studies were conducted on 20 – 30 HIV positive patients, under supervision of one of South Africa’s top HIV/AIDS specialists, Dr Steven Miller. Due to the excellent results achieved, a follow-up study on approximately 100 patients was done with the permission of the South African Medicine Control Council, first for six months, and then for a follow-up period of up to two years. The results of this trial were presented at the International HIV conference in Yokohama, Japan in 1994.

With the help and financial support of the Industrial Development Corporation (IDC), an even larger, longer-term double-blind, placebo-controlled trial was started in 1997. Preliminary results of this trial were presented at the International HIV/AIDS Conference in Geneva, Switzerland in 1998, and the Amino Acid Conference in Vienna, Austria in 2001.

These clinical trials were done under the registered trademark of Equimmune, and were aimed specifically at the HIV/AIDS market.

Bio Boost formulation
A second product was formulated, with a slightly adjusted dosage, under the trademark Bio Boost. The formulation proved to be effective for any patient with a low or deficient immune system, whether due to chronic fatigue, extreme stress and tension or common cold and flu.

A farmavita member is offering aa immune-supporting supplement product for Europe, USA, MIDDLE EAST, & AFRICA.

 Introduction and initial research
Research on this patented formulation (containing L-methionine, magnesium, vitamin B6, B12 and folic acid), started as early as 1992, at the University of Pretoria, South Africa. Pilot studies were conducted on 20 – 30 HIV positive patients, under supervision of one of South Africa’s top HIV/AIDS specialists, Dr Steven Miller. Due to the excellent results achieved, a follow-up study on approximately 100 patients was done with the permission of the South African Medicine Control Council, first for six months, and then for a follow-up period of up to two years. The results of this trial were presented at the International HIV conference in Yokohama, Japan in 1994.

With the help and financial support of the Industrial Development Corporation (IDC), an even larger, longer-term double-blind, placebo-controlled trial was started in 1997. Preliminary results of this trial were presented at the International HIV/AIDS Conference in Geneva, Switzerland in 1998, and the Amino Acid Conference in Vienna, Austria in 2001.

These clinical trials were done under the registered trademark of Equimmune, and were aimed specifically at the HIV/AIDS market.

Bio Boost formulation
A second product was formulated, with a slightly adjusted dosage, under the trademark Bio Boost. The formulation proved to be effective for any patient with a low or deficient immune system, whether due to chronic fatigue, extreme stress and tension or common cold and flu.

Recombinant FSH and Inteferon beta

Member of Farmavita.Net is seeking a co-licensing agreement with a pharmaceutical company to set up a GMP production line for recombinant FSH and recombinant Inteferon beta.